The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
Abstract
Purpose: This randomized study compared denosumab, a fully human monoclonal antibody against receptor activator of nuclear factor κ B (RANK) ligand, with zoledronic acid in delaying or preventing skeletal-related events (SREs) in patients with breast cancer with bone metastases. Patients and Methods: Patients were randomly assigned to receive either subcutaneous denosumab 120 mg and intravenous placebo (n = 1,026) or intravenous zoledronic acid 4 mg adjusted for creatinine clearance and subcutaneous placebo (n = 1,020) every 4 weeks. All patients were strongly recommended to take daily calcium and vitamin D supplements. The primary end point was time to first on-study SRE (defined as pathologic fracture, radiation or surgery to bone, or spinal cord compression). Results: Denosumab was superior to zoledronic acid in delaying time to first on-study SRE (hazard ratio, 0.82; 95% CI, 0.71 to 0.95; P = .01 superiority) and time to first and subsequent (multiple) on-study SREs (rate ratio, 0.77; 95% CI, 0.66 to 0.89; P = .001). Reduction in bone turnover markers was greater with denosumab. Overall survival, disease progression, and rates of adverse events (AEs) and serious AEs were similar between groups. An excess of renal AEs and acute-phase reactions occurred with zoledronic acid; hypocalcemia occurred more frequently with denosumab. Osteonecrosis of the jaw occurred infrequently (2.0%, denosumab; 1.4%, zoledronic acid; P = .39). Conclusion: Denosumab was superior to zoledronic acid in delaying or preventing SREs in patients with breast cancer metastatic to bone and was generally well tolerated. With the convenience of a subcutaneous injection and no requirement for renal monitoring, denosumab represents a potential treatment option for patients with bone metastases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Cox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Roodman, G. D. (2004) · New England Journal of Medicine · doi:10.1056/nejmra030831 · Cited by 2,755
Metastatic bone disease: clinical features, pathophysiology and treatment strategies
Coleman, R. E. (2001) · Cancer Treatment Reviews · doi:10.1053/ctrv.2000.0210 · Cited by 1,920
Skeletal complications of malignancy
Coleman, R. E. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971015)80:8+<1588::aid-cncr9>3.0.co;2-g · Cited by 1,502
Denosumab in postmenopausal women with low bone mineral density.
McClung, M. R., Lewiecki, E. M., Cohen, S. B., Bolognese, M. A., Woodson, G. C., Moffett, A. H., Peacock, M., Miller, P. D., Lederman, S. N., Chesnut, C. H., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044459 · Cited by 1,228
Hortobagyi, G. N., Theriault, R. L., Porter, L., Blayney, D., Lipton, A., Sinoff, C., Wheeler, H., Simeone, J. F., Seaman, J., Knight, R. D., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612123352401 · Cited by 1,026
Self-citationHillner, B. E., Ingle, J. N., Chlebowski, R. T., Gralow, J., Yee, G. C., Janjan, N. A., Cauley, J. A., Blumenstein, B. A., Albain, K. S., Lipton, A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.017 · Cited by 970
Self-citationRosen, L. S., Gordon, D., Kaminski, M., Howell, A., Belch, A. R., Mackey, J. R., Apffelstaedt, J., Hussein, M., Coleman, R. E., Reitsma, D. J., et al. (2001) · PubMed · Cited by 896
Cited by
Osteoporosis: now and the future
Rachner, T. D., Khosla, S., & Hofbauer, L. C. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62349-5 · Cited by 2,696
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
Fizazi, K., Carducci, M., Smith, M., Damião, R., Brown, J., Karsh, L., Milecki, P., Shore, N., Rader, M., Wang, H., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62344-6 · Cited by 1,971
Self-citationBreast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0016 · Cited by 1,584
Awareness and current knowledge of breast cancer
Akram, M., Iqbal, M., Daniyal, M., & Khan, A. U. (2017) · Biological Research · doi:10.1186/s40659-017-0140-9 · Cited by 1,406
Steeg, P. S. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.25 · Cited by 1,363
Khan, A. A., Morrison, A., Hanley, D. A., Felsenberg, D., McCauley, L. K., O'Ryan, F., Reid, I. R., Ruggiero, S. L., Taguchi, A., Tetradis, S., et al. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2405 · Cited by 1,353
Cancer to bone: a fatal attraction
Weilbaecher, K. N., Guise, T. A., & McCauley, L. K. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3055 · Cited by 1,285
Ruggiero, S. L., Dodson, T. B., Aghaloo, T., Carlson, E. R., Ward, B. B., & Kademani, D. (2022) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2022.02.008 · Cited by 1,141
Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines
Fallon, M., Giusti, R., Aielli, F., Hoskin, P., Rolke, R., Sharma, M., & Ripamonti, C. I. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy152 · Cited by 954
American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
Smallridge, R. C., Ain, K. B., Asa, S. L., Bible, K. C., Brierley, J. D., Burman, K. D., Kebebew, E., Lee, N. Y., Nikiforov, Y. E., Rosenthal, M. S., et al. (2012) · Thyroid · doi:10.1089/thy.2012.0302 · Cited by 935
Smith, M. R., Saad, F., Coleman, R., Shore, N., Fizazi, K., Tombal, B., Miller, K., Sieber, P., Karsh, L., Damião, R., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61226-9 · Cited by 797
Self-citationMacedo, F., Ladeira, K., Pinho, F., Saraiva, N., Bonito, N., Pinto, L., & Gonçalves, F. (2017) · Oncology Reviews · doi:10.4081/oncol.2017.321 · Cited by 775
Bible, K. C., Kebebew, E., Brierley, J., Brito, J. P., Cabanillas, M. E., Clark, T. J., Di Cristofano, A., Foote, R., Giordano, T., Kasperbauer, J., et al. (2021) · Thyroid · doi:10.1089/thy.2020.0944 · Cited by 730
Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab
Lacey, D. L., Boyle, W. J., Simonet, W. S., Kostenuik, P. J., Dougall, W. C., Sullivan, J. K., Martin, J. S., & Dansey, R. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3705 · Cited by 694
Self-citationCardoso, F., Fallowfield, L., Costa, A., Castiglione, M., & Senkus, E. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr372 · Cited by 596
Lipton, A., Fizazi, K., Stopeck, A. T., Henry, D. H., Brown, J. E., Yardley, D. A., Richardson, G. E., Siena, S., Maroto, P., Clemens, M., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.08.002 · Cited by 588
Self-citationChawla, S., Henshaw, R., Seeger, L., Choy, E., Blay, J.-Y., Ferrari, S., Kroep, J., Grimer, R., Reichardt, P., Rutkowski, P., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70277-8 · Cited by 587
Coleman, R. E., Croucher, P. I., Padhani, A. R., Clézardin, P., Chow, E., Fallon, M., Guise, T., Colangeli, S., Capanna, R., & Costa, L. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00216-3 · Cited by 570
Bone health in cancer patients: ESMO Clinical Practice Guidelines
Coleman, R., Body, J. J., Aapro, M., Hadji, P., & Herrstedt, J. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu103 · Cited by 564
Self-citationBone health in cancer: ESMO Clinical Practice Guidelines
Coleman, R., Hadji, P., Body, J.-J., Santini, D., Chow, E., Terpos, E., Oudard, S., Bruland, Ø., Flamen, P., Kurth, A., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.019 · Cited by 549
Self-citationOsteoimmunology: The conceptual framework unifying the immune and skeletal systems
Okamoto, K., Nakashima, T., Shinohara, M., Negishi-Koga, T., Komatsu, N., Terashima, A., Sawa, S., Nitta, T., & Takayanagi, H. (2017) · Physiological Reviews · doi:10.1152/physrev.00036.2016 · Cited by 534
Understanding the Bone in Cancer Metastasis
Fornetti, J., Welm, A. L., & Stewart, S. A. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3618 · Cited by 526
Tissue invasion and metastasis: Molecular, biological and clinical perspectives
Jiang, W. G., Sanders, A. J., Katoh, M., Ungefroren, H., Gieseler, F., Prince, M., Thompson, S. K., Zollo, M., Spano, D., Dhawan, P., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.008 · Cited by 515
Cardoso, F., Harbeck, N., Fallowfield, L., Kyriakides, S., & Senkus, E. (2012) · Annals of Oncology · doi:10.1093/annonc/mds232 · Cited by 485
Palliative radiation therapy for bone metastases: Update of an ASTRO Evidence-Based Guideline
Lutz, S., Balboni, T., Jones, J., Lo, S., Petit, J., Rich, S. E., Wong, R., & Hahn, C. (2017) · Practical Radiation Oncology · doi:10.1016/j.prro.2016.08.001 · Cited by 465
Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone
Branstetter, D. G., Nelson, S. D., Manivel, J. C., Blay, J.-Y., Chawla, S., Thomas, D. M., Jun, S., & Jacobs, I. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0578 · Cited by 426
Self-citationBone metastasis: mechanisms and therapeutic opportunities
Suva, L. J., Washam, C., Nicholas, R. W., & Griffin, R. J. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.227 · Cited by 424
Bone metastasis: mechanisms, therapies, and biomarkers
Clézardin, P., Coleman, R., Puppo, M., Ottewell, P., Bonnelye, E., Paycha, F., Confavreux, C. B., & Holen, I. (2021) · Physiological Reviews · doi:10.1152/physrev.00012.2019 · Cited by 416
The microenvironment in breast cancer progression: biology and implications for treatment
Place, A. E., Jin Huh, S., & Polyak, K. (2011) · Breast Cancer Research · doi:10.1186/bcr2912 · Cited by 413
NCCN Task Force Report: Bone Health in Cancer Care
Gralow, J. R., Biermann, J. S., Farooki, A., Fornier, M. N., Gagel, R. F., Kumar, R., Litsas, G., McKay, R., Podoloff, D. A., Srinivas, S., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0215 · Cited by 412
Unravelling the complexity of metastasis — molecular understanding and targeted therapies
Sethi, N., & Kang, Y. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3125 · Cited by 397
Hellstein, J. W., Adler, R. A., Edwards, B., Jacobsen, P. L., Kalmar, J. R., Koka, S., Migliorati, C. A., & Ristic, H. (2011) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2011.0108 · Cited by 363
Nicolatou-Galitis, O., Schiødt, M., Mendes, R. A., Ripamonti, C., Hope, S., Drudge-Coates, L., Niepel, D., & Van den Wyngaert, T. (2019) · Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology · doi:10.1016/j.oooo.2018.09.008 · Cited by 361
Bisphosphonates and other bone agents for breast cancer
O'Carrigan, B., Wong, M. H., Willson, M. L., Stockler, M. R., Pavlakis, N., & Goodwin, A. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003474.pub4 · Cited by 356
Tilki, D., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Brunckhorst, O., Darraugh, J., Eberli, D., De Meerleer, G., De Santis, M., Farolfi, A., et al. (2024) · European Urology · doi:10.1016/j.eururo.2024.04.010 · Cited by 352
Van Poznak, C. H., Temin, S., Yee, G. C., Janjan, N. A., Barlow, W. E., Biermann, J. S., Bosserman, L. D., Geoghegan, C., Hillner, B. E., Theriault, R. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.5209 · Cited by 342
A framework for the development of effective anti-metastatic agents
Anderson, R. L., Balasas, T., Callaghan, J., Coombes, R. C., Evans, J., Hall, J. A., Kinrade, S., Jones, D., Jones, P. S., Jones, R., et al. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0134-8 · Cited by 341
A single-dose study of denosumab in patients with various degrees of renal impairment
Block, G. A., Bone, H. G., Fang, L., Lee, E., & Padhi, D. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1613 · Cited by 340
Management of cancer pain: ESMO Clinical Practice Guidelines
Ripamonti, C. I., Santini, D., Maranzano, E., Berti, M., & Roila, F. (2012) · Annals of Oncology · doi:10.1093/annonc/mds233 · Cited by 329
Marino, N., Woditschka, S., Reed, L. T., Nakayama, J., Mayer, M., Wetzel, M., & Steeg, P. S. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.06.012 · Cited by 309
Bone cancer pain: Causes, consequences, and therapeutic opportunities
Mantyh, P. (2013) · Pain · doi:10.1016/j.pain.2013.07.044 · Cited by 306
Fugazzola, L., Elisei, R., Fuhrer, D., Jarzab, B., Leboulleux, S., Newbold, K., & Smit, J. (2019) · European Thyroid Journal · doi:10.1159/000502229 · Cited by 285
Murad, M. H., Drake, M. T., Mullan, R. J., Mauck, K. F., Stuart, L. M., Lane, M. A., Abu Elnour, N. O., Erwin, P. J., Hazem, A., Puhan, M. A., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3060 · Cited by 277
New targets and approaches in osteosarcoma
Gill, J., Ahluwalia, M. K., Geller, D., & Gorlick, R. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.09.003 · Cited by 273
Khan, A. A., Morrison, A., Kendler, D. L., Rizzoli, R., Hanley, D. A., Felsenberg, D., McCauley, L. K., O'Ryan, F., Reid, I. R., Ruggiero, S. L., et al. (2017) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2016.09.005 · Cited by 264
Bone Pain in Cancer Patients: Mechanisms and Current Treatment
Zajączkowska, R., Kocot-Kępska, M., Leppert, W., & Wordliczek, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20236047 · Cited by 262
Denosumab treatment for fibrous dysplasia
Boyce, A. M., Chong, W. H., Yao, J., Gafni, R. I., Kelly, M. H., Chamberlain, C. E., Bassim, C., Cherman, N., Ellsworth, M., Kasa-Vubu, J. Z., et al. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1603 · Cited by 260
Bone metastasis in prostate cancer: emerging therapeutic strategies
Sturge, J., Caley, M. P., & Waxman, J. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.67 · Cited by 256
Metastatic bone disease: Pathogenesis and therapeutic options
D'Oronzo, S., Coleman, R., Brown, J., & Silvestris, F. (2019) · Journal of Bone Oncology · doi:10.1016/j.jbo.2018.10.004 · Cited by 255
Henry, D., Vadhan-Raj, S., Hirsh, V., von Moos, R., Hungria, V., Costa, L., Woll, P. J., Scagliotti, G., Smith, G., Feng, A., et al. (2014) · Supportive Care in Cancer · doi:10.1007/s00520-013-2022-1 · Cited by 183
RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives
Infante, M., Fabi, A., Cognetti, F., Gorini, S., Caprio, M., & Fabbri, A. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-1001-2 · Cited by 180
Therapy-Induced Senescence Drives Bone Loss
Yao, Z., Murali, B., Ren, Q., Luo, X., Faget, D. V., Cole, T., Ricci, B., Thotala, D., Monahan, J., van Deursen, J. M., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2348 · Cited by 129
Symptom Management in Metastatic Breast Cancer
Irvin, W., Muss, H. B., & Mayer, D. K. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0159 · Cited by 112
Subcutaneous Administration of Monoclonal Antibodies in Oncology
Jackisch, C., Müller, V., Maintz, C., Hell, S., & Ataseven, B. (2014) · Geburtshilfe und Frauenheilkunde · doi:10.1055/s-0034-1368173 · Cited by 90
Brumm, M. C., Siderowf, A., Simuni, T., Burghardt, E., Choi, S. H., Caspell-Garcia, C., Chahine, L. M., Mollenhauer, B., Foroud, T., Galasko, D., et al. (2023) · Journal of Parkinson’s Disease · doi:10.3233/jpd-223433 · Cited by 70
Yang, C., Davis, J. L., Zeng, R., Vora, P., Su, X., Collins, L. I., Vangveravong, S., Mach, R. H., Piwnica-Worms, D., Weilbaecher, K. N., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0271 · Cited by 50
Bone metastases from hepatocellular carcinoma: clinical features and prognostic factors
Lu, Y., Hu, J.-G., Lin, X.-J., & Li, X.-G. (2017) · Hepatobiliary & Pancreatic Diseases International · doi:10.1016/s1499-3872(16)60173-x · Cited by 26
Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation
Kotsopoulos, J., Gronwald, J., Huzarski, T., Aeilts, A., Randall Armel, S., Karlan, B., Singer, C. F., Eisen, A., Tung, N., Olopade, O., et al. (2023) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-06991-3 · Cited by 26
A review of mathematical modeling of bone remodeling from a systems biology perspective
Cook, C. V., Lighty, A. M., Smith, B. J., & Ford Versypt, A. N. (2024) · Frontiers in Systems Biology · doi:10.3389/fsysb.2024.1368555 · Cited by 25
Cristino, J., Finek, J., Jandova, P., Kolek, M., Pásztor, B., Giannopoulou, C., Qian, Y., Brezina, T., & Lothgren, M. (2017) · Journal of Medical Economics · doi:10.1080/13696998.2017.1328423 · Cited by 16
Metadata
- Authors
- Stopeck, A. T., Lipton, A., Body, J.-J., Steger, G. G., Tonkin, K., de Boer, R. H., Lichinitser, M., Fujiwara, Y., Yardley, D. A., Viniegra, M., Fan, M., Jiang, Q., Dansey, R., Jun, S., & Braun, A.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-12-10
- Volume
- 28
- Issue
- 35
- Pages
- 5132-5139
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2165011173
- Cited by
- 1,597
- References
- 32
- FWCI
- 66.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.